Menu |
The Drug
Repurposing Hub
Drug Repurposing Hub
Resource for the advancement
of therapeutic discovery
Resource for the advancement of therapeutic discovery
Drug repurposing experiments are limited by the lack of comprehensive screening libraries. We introduce a best-in-class drug screening collection with more than 3,000 clinical drugs. The Repurposing Hub information resource contains extensive curated annotations for each drug, including a complete blueprint for library assembly. Drugs will be systematically profiled across cellular gene expression, cytotoxicity, morphology, and proteomic assays. We invite you to explore the Hub information resource as a first step towards discovering new therapeutic applications for existing drugs.
the Library
6,883Total Samples
2,062Protein Targets
4,737Unique Compounds
641Drug Indications

About the Drug Repurposing Hub

Drug repurposing aims to discover new indications for existing drugs with known safety profiles. The advent of high-throughput technologies to systematically evaluate drug effects across different cellular contexts enables such discoveries. However, determining a complete list of clinical drugs and obtaining these compounds for laboratory use is surprisingly challenging. To address this challenge, we integrated multiple public and proprietary data sources with chemical vendor catalogs.

The Drug Repurposing Hub is a close collaboration between the Broad Institute Cancer Program, Center for the Development of Therapeutics, and the Connectivity Map group. The Hub consists of 1) a physical drug screening library available in multiple plate formats at the Broad Compound Management facility, 2) manually curated annotations as part of a comprehensive publicly-accessible information resource with data API, and 3) experimental results with LC-MS tracings and future cellular assays. Active engagement of the user community is planned via drug library additions and deposition of new assay results.


Currently, the repurposing library is being profiled at the Broad Institute using the assay technologies below. Additional screens are in the planning stages.

  • L1000 perturbational gene expression profiling to evaluate and score changes in gene expression. Gene expression signatures will be compared to reference genetic and chemical perturbations collected as part of the NIH Library of Integrated Network-based Cellular Signatures (LINCS) project.
  • PRISM pooled cell viability assay to detect cell line-specific cytotoxicity for over 500 cell lines. Cytotoxicity profiles will be compared to baseline cell line features from the Cancer Cell Line Encyclopedia (CCLE) to predict biomarkers of drug response.
  • Cell Painting morphology assessment to image and quantify changes in over 900 cellular features.
  • Multidimensional proteomic assays including P100 and GCP will be used to profile a subset of library compounds.

Screening Library

More than 6,000 compound samples were purchased from 50 different suppliers. Each compound has been assayed for purity, registered in the Broad compound management system, and annotated for structure, clinical development status, vendor information, mechanism of action, protein targets, and approved indications. Explore library contents now via the Repurposing Hub web application.

Data Access


We encourage use of the data API for real-time updates. Exports of a subset of the underlying data tables will be provided at regular intervals. Login is required for download access. Repurposing Hub data is provided for non-commercial use only. Please contact repurposing@broad to discuss any commercial applications.

API Access

The Repurposing Hub database is available via a RESTful web service using the JSON text-based message format. Registration is required to obtain a user-specific API key. The examples below use a limited demonstration key.

Sample API queries (See Repurposing CLUE API documentation for more information):

List the MoAs of tacrolimus:

List compounds with moa "calcineurin inhibitor":
/api/moas/?filter={"where":{"name":"calcineurin inhibitor"},"fields":{"pert_iname":true}}

List clinical status of tacrolimus:

List genes targets of tacrolimus:

Information sources

Proprietary sources

Several proprietary databases were used in the initial library design and summary analyses. Due to licensing restrictions we cannot provide exports from these resources.


We thank the curators of public drug databases, our chemical vendors, and assay teams. We gratefully acknowledge funding sources including the Broad Next10 initiative, NIH LINCS Program grant 3U54 HG006093, NIH BD2K Program grant 5U01HG008699, NIH training grant T32 CA009172 and Conquer Cancer Foundation of ASCO Young Investigator Award.

Contact Drug Repurposing